Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124318 | 0.90 | BTK (0.55) | BTKKDM4ERAB9ACLK2TYK2 | |
| SCHEMBL3963393 | 0.86 | BTK (0.71) | BTKKDM4ERAB9ACLK2 | |
| SCHEMBL13894025 | 0.85 | BTK (0.67) | BTKKDM4ERAB9ACLK2SRC | |
| SCHEMBL1322606 | 0.83 | BTK (0.77) | BTKCLK2SRC | |
| SCHEMBL4085845 | 0.82 | BTK (0.59) | BTKKDM4ERAB9ACLK2TYK2 | |
| SCHEMBL3750774 | 0.81 | NPC1 (0.42) | KDM4ERAB9A | |
| SCHEMBL3660016 | 0.81 | BTK (0.62) | BTKKDM4ERAB9ACLK2TYK2 | |
| SCHEMBL3968942 | 0.80 | BTK (0.51) | BTK | |
| SCHEMBL3654050 | 0.79 | BTK (0.50) | BTKKDM4ERAB9ACLK2TYK2 | |
| SCHEMBL1321960 | 0.79 | BTK (0.58) | BTKKDM4ERAB9ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081923-B1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2081923-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | BTK 1/4885KDM4E 845/4885RAB9A 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.